Siemens Healthineers has introduced two new assays for quick diagnosis of acute myocardial infarction or heart attack, following approval from the US Food and Drug Administration (FDA).

The High-Sensitivity Troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in-vitro diagnostic analysers are designed to detect low cardiac troponin I levels in serum or plasma.

The new assays are expected to support testing initiatives by using data to correctly triage patients early or rule out myocardial infarctions.

According to Siemens, the TnIH assays leverage the company’s technology with three new monoclonal antibodies and are set to provide better patient care with high-sensitivity cardiac troponin detection.